derazantinib
Derazantinib is a drug used to treat Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma, and Gastric Adenocarcinoma. Derazantinib is being actively studied in 3 studies; no studies for this drug have been completed so far.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Basilea Pharmaceutica | Beatson West of Scotland Cancer Centre | |
Institut fur Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Fondazione IRCCS Istituto Nazionale dei Tumori | |
Samsung Medical Center |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
I
Recruiting
- Intrahepatic Cholangiocarcinoma
- Atezolizumab
- Derazantinib
- Bad Saarow, GermanyHELIOS KLinikum Bad Saarow
2022-03-29
Mar 29, 2022B
Available
- Intrahepatic Cholangiocarcinoma
- derazantinib
- (no location specified)
2021-06-17
Jun 17, 2021B
Recruiting
- Intrahepatic Cholangiocarcinoma
- Combined Hepatocellular and Cholangiocarcinoma
- derazantinib
- Phoenix, Arizona
- +40 more
2022-03-07
Mar 7, 2022B
Recruiting
- Gastric Adenocarcinoma
- Derazantinib
- +3 more
- Gilbert, Arizona
- +82 more
2022-03-07
Mar 7, 2022